Navigation Links
Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement
Date:5/27/2009

NORCROSS, Ga., May 27 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has signed a five-year agreement with Alverno Clinical Laboratories, LLC, one of the largest regional hospital laboratory integrated delivery systems in the nation, serving 27 hospitals in Illinois and Indiana.

Under the agreement, Alverno is standardizing pre-transfusion testing in 26 facilities with Immucor automation through the acquisition of 24 Echo instruments and 2 Capture Workstations. Additionally, Immucor will be the primary source for Alverno's blood bank reagent needs.

"We are pleased to partner with such an innovative organization as Alverno," stated Dr. Gioacchino De Chirico, President and Chief Executive Officer of Immucor. "We believe that integrated delivery networks can achieve significant benefits both in terms of improving operational efficiency and improving patient safety through standardizing their blood bank operations with Immucor automation."

"Our goal is to produce accurate and timely test results while implementing standardized best practices across all laboratory sites," stated Sam Terese, Chief Operating Officer of Alverno Clinical Laboratories. "We chose Immucor due to the exceptional functionality of the Echo instrument and its fit with LEAN operations as well as Immucor's commitment to improving transfusion medicine."

Immucor's innovative automation strategy provides scalable solutions to meet the needs of all blood banks, regardless of size. Immucor has continually invested in automation since 1998, most recently with the Echo instrument. The Echo, which is designed for smaller volume laboratories, features a broad test menu, instant access and the industry's fastest turnaround times.

About Alverno Clinical Laboratories

Located in Hammond, In., Alverno Clinical Laboratories, LLC is one of the largest regional hospital laboratory integrated delivery systems in the nation. Alverno's operations include a regional core laboratory, 27 hospital laboratories, and a network of patient service centers in both Indiana and Illinois. Alverno is a joint venture of the Sisters of St. Francis Health Services, Inc., Resurrection Health Care and Provena Health. For more information on Alverno, please visit our website at www.alvernoclinicallabs.com.

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Immucor Schedules Second Quarter Earnings Release and Conference Call
2. FDA Accepts Immucors Response to Warning Letter
3. Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance
4. Immucor CEOs Italian Trial Moves Toward Second Phase
5. Immucor To Acquire BioArray Solutions Ltd.
6. Immucor Responding to FTC Inquiry
7. Immucor Settles SEC Investigation
8. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
9. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
10. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
11. Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
Breaking Biology Technology:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):